When was Kineta founded?

Kineta was founded in 2008 and raised its 1st funding round within a year of its incorporation.

Where is Kineta located?

Kineta is headquartered in Seattle, United States.

Is Kineta a funded company?

Kineta is a funded company, having raised a total of $127M across 43 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 05, 2008.

How much is Kineta worth?

The last known valuation of Kineta was $***** as of Feb 06, 2025.

When was the latest funding round of Kineta?

Kineta's latest funding was a $***** Series D round on Jun 13, 2022, with participation from 0 investor.

What is the annual revenue of Kineta?

Annual revenue of Kineta is between $1M and $10M as on Dec 31, 2023

Where does Kineta rank among its competitors?

Kineta ranks 2nd amongst 24 active competitors, of which 5 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Immunophotonics, which secured $1.52M in Feb, 2024.

Who are the top competitors of Kineta?

Kineta's top competitors include Emergent BioSolutions, Immunophotonics and Quratis. Among them, Immunophotonics secured the most recent funding round in February, 2024.

Kineta - 2026 Company Profile, Team, Funding, Competitors & Financials

Kineta is an acquired company based in Seattle (United States), founded in 2008 by Charles Magness, Charles Magness and Shawn Iadonato. It operates as a Developing immune-modulating therapeutics and vaccine adjuvants for autoimmune and infectious diseases. Kineta has raised $127M in funding from Cheongbo Industrial, with last known valuation of $*****. The company has 24 active competitors, including 5 funded and 7 that have exited. Its top competitors include companies like Emergent BioSolutions, Immunophotonics and Quratis.

Company Details

Kineta is focused on developing immune-modulating therapeutics and vaccine adjuvants for autoimmune and infectious diseases. Autoimmune disease pipeline includes dalazitide in clinical trial phase 1B for Lupus, Psoriasis, Psoriatic Arthritis, RA, MS, Vasculitis, IBD, Asthma, AD, Type 1 diabetes (T1D). Antiviral pipeline includes compounds of preclinical categories innate-immune antivirals, vaccine adjuvants and direct-acting antivirals all of which discovered using its proprietary aviid antiviral discovery platform. It also has a chronic pain candidate in preclinical stage for diabetic nephropathy and traumatic injury

Website: www.kinetabio.com/
Social

Key Metrics

Founded Year

2008

Location

Seattle, United States

Stage

Acquired

Total Funding

$127M in 43 rounds

Latest Funding Round

Series D, Jun 13, 2022, $*****

Last Known Valuation

$***** as on Feb 06, 2025

Investors

Cheongbo Industrial & 11 more

Ranked

2^nd among 24 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2023

Similar Companies

Emergent BioSolutions & 30 more

Exit Details

Acquired by TuHURA Biosciences (Feb 06, 2025)

View Kineta's full profile

Kineta is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
KINETA, INC./DE CIN: 1445283 , United States, Active		$1M - $10M (As on Dec 31, 2023)	41 (As on Dec 31, 2021)	-
Kineta, Inc. CIN: 261566793 , United States, Active		-	4 (As on Dec 31, 2024)	-

Kineta got acquired by TuHURA Biosciences on Feb 06, 2025.

Click here to take a look at Kineta's acquisition in detail

Kineta has raised a total funding of $127M over 43 rounds. Its first funding round was on Sep 05, 2008. Kineta has 12 institutional investors.

Here is the list of recent funding rounds of Kineta:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 13, 2022	4421944	Series D	9081113	2817229	8837927	1582702
Feb 25, 2022	3835296	Series D	8744494	1265719	5125717	4668868
Jun 29, 2021	3087936	Series D	8712035	2059088	8498493	9801148

Access funding benchmarks and valuations. Sign up today!

View details of Kineta's funding rounds and investors

The founders of Kineta are Charles Magness, Charles Magness and Shawn Iadonato.

Here are the details of Kineta's key team members:

Charles Magness: Co-Founder of Kineta and founder of 1 other company.
Charles Magness: Co-Founder of Kineta.
Shawn Iadonato: Founder of Kineta.

View details of Kineta's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kineta include Emergent BioSolutions, Immunophotonics and Quratis. Here is the list of Top 10 competitors of Kineta, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Emergent BioSolutions 1998, Gaithersburg (United States), Public	Developer of vaccines primarily for virus infections	-	Advent Life Sciences, NISA & 12 others	69/100
2nd	Kineta 2008, Seattle (United States), Acquired	Developing immune-modulating therapeutics and vaccine adjuvants for autoimmune and infectious diseases	$127M	Pfizer, NIAID & 10 others	58/100
3rd	Immunophotonics 2008, St. Louis (United States), Series B	Developer of therapeutics for the treatment of interventional immuno-oncology	$28.1M	Zubizoom, ROVAQ Ventures & 12 others	56/100
4th	Quratis 2016, Seoul (South Korea), Seed	Developer of vaccines and cell therapies for treating tuberculosis	-	STIC Ventures, Aju IB Investment & 3 others	45/100
5th	Adjuvance Technologies 2009, New York City (United States), Series A	Involved in vaccine adjuvant design and manufacturing.	$13.4M	Morningside, Mont Alto Capital & 5 others	40/100
6th	MaxiVAX 2006, Geneva (Switzerland), Series B	Developing immunotherapies for treating cancer	$5.01M	EIC Fund, European Innovation Council & 2 others	36/100
7th	Coley Pharmaceutical 1997, Wellesley (United States), Acquired	Immunomodulatory drugs and vaccine adjuvants	$55M	Thuja Capital, Venrock & 3 others	35/100
8th	Juvaris 2001, Burlingame (United States), Deadpooled	Develops adjuvanted vaccines and immunotherapeutics to treat cancer and infectious diseases	$15.9M	SV Health Investors, TriplePoint Capital & 2 others	35/100
9th	EyeGene 2000, Seoul (South Korea), Public	Developer of immune vaccines and diagnostic systems for eye disorders	-	Hanwha Investment, GNTech Venture Capital ... & 6 others	35/100
10th	Isconova 1999, Uppsala (Sweden), Acquired	Vaccine Adjuvants for Infectious DIseases and Veterinary Markets	$5.02M	InnovationsKapital	31/100